id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-0030-53769,FDA,FDA-2015-N-0030,"Supplement from Novo Nordisk, Inc.",Other,Supplement (SUP),2025-04-29T04:00:00Z,2025,4,2025-04-29T04:00:00Z,,2025-04-29T19:32:09Z,,0,0,0900006486abc35f
FDA-2015-N-0030-8513,FDA,FDA-2015-N-0030,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2023-02-14T05:00:00Z,2023,2,2023-02-14T05:00:00Z,,2023-02-14T14:51:29Z,2023-03073,0,0,090000648569352b
FDA-2015-N-0030-8512,FDA,FDA-2015-N-0030,Extension of the Period Before the Food and Drug Administration Intends to Begin Enforcing the Statutory 5 Percent Limit on Out-of-State Distribution of Compounded Human Drug Products,Rule,Extension of Comment Period,2022-10-21T04:00:00Z,2022,10,2022-10-21T04:00:00Z,,2022-10-21T12:22:13Z,2022-22876,0,0,0900006485442443
FDA-2015-N-0030-8511,FDA,FDA-2015-N-0030,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",Notice,30 Day Proposed Information Collection,2022-10-07T04:00:00Z,2022,10,2022-10-07T04:00:00Z,,2022-10-07T17:13:32Z,2022-21841,0,0,09000064853d45d8
FDA-2015-N-0030-8509,FDA,FDA-2015-N-0030,"Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act",Notice,60 Day Proposed Information Collection,2022-06-17T04:00:00Z,2022,6,2022-06-17T04:00:00Z,2022-08-17T03:59:59Z,2022-09-19T19:18:53Z,2022-13068,0,0,0900006485178b8f
FDA-2015-N-0030-8507,FDA,FDA-2015-N-0030,Memorandum of Meeting from FDA/CDER,Other,Memorandum,2021-12-01T05:00:00Z,2021,12,2021-12-01T05:00:00Z,,2021-12-01T21:02:19Z,,0,0,0900006484e8cda7
FDA-2015-N-0030-8506,FDA,FDA-2015-N-0030,Extension of the Period Before the Food and Drug Administration Intends To Begin Enforcing the Statutory 5 Percent Limit on Out of State Distribution of Compounded Human Drug Products,Notice,Extension of Compliance Date,2021-08-09T04:00:00Z,2021,8,2021-08-09T04:00:00Z,,2021-08-09T13:10:59Z,2021-16937,0,0,0900006484c365db
FDA-2015-N-0030-8455,FDA,FDA-2015-N-0030,"Memorandum of Understanding Addressing Certain Distributions of
Compounded Human Drug Products Between the State Board of Pharmacy or Other Appropriate State Agency and the Food and Drug Administration; Availability",Notice,Withdrawal,2020-10-27T04:00:00Z,2020,10,2020-10-27T04:00:00Z,,2020-10-27T13:41:21Z,2020-23687,0,0,090000648493647e
FDA-2015-N-0030-8454,FDA,FDA-2015-N-0030,Final Standard MOU Addressing Certain Distributions of Compounded Human Drug Products - For Implementation,Other,Additional Information,2020-10-26T04:00:00Z,2020,10,2020-10-26T04:00:00Z,,2020-10-26T12:19:15Z,,0,0,090000648492e60e
FDA-2015-N-0030-0327,FDA,FDA-2015-N-0030,Letter from Avella to FDA DDM,Other,Letter(s),2018-08-15T04:00:00Z,2018,8,2018-08-15T04:00:00Z,,2018-08-15T18:40:04Z,,0,0,0900006483626771
FDA-2015-N-0030-0316,FDA,FDA-2015-N-0030,Testimony from International Academy of Compounding Pharmacists (IACP),Other,Testimony,2017-06-09T04:00:00Z,2017,6,2017-06-09T04:00:00Z,,2017-06-09T15:38:19Z,,0,0,09000064826aef0f
FDA-2015-N-0030-0060,FDA,FDA-2015-N-0030,Testimony from National Home Infusion Association,Other,Testimony,2016-06-23T04:00:00Z,2016,6,2016-06-23T04:00:00Z,,2016-06-23T19:59:14Z,,0,0,0900006482046fd4
FDA-2015-N-0030-0001,FDA,FDA-2015-N-0030,"Compounding of Human Drug Products Under the Federal Food,
Drug, and Cosmetic Act; Establishment of a Public Docket",Notice,Requests for Information (RFI),2015-03-09T05:00:00Z,2015,3,2015-03-09T05:00:00Z,,2026-02-20T20:29:40Z,2015-05376,1,0,0900006481a33cbd